argenx says Phase 2 trial shows FB102 significantly improves Vh:Cd ratio in celiac disease gluten challenge
ARGX•argenx reported positive topline Phase 2 results for FB102 in a celiac disease gluten challenge, with significant improvement in the Vh:Cd ratio versus placebo. The results support moving into Phase 3 development; no new safety concerns emerged.
1. Phase 2 results
Patients receiving FB102 showed reduced gluten-driven intestinal injury versus placebo during a controlled gluten challenge. Secondary measures, including inflammation signals and patient-reported symptoms, aligned with the main outcome, and the safety profile matched prior studies with no new concerns. Detailed data will be presented at a future medical meeting.
